Narrowband UV-B (TL-01) Phototherapy vs Oral 8-Methoxypsoralen Psoralen–UV-A for the Treatment of Chronic Plaque Psoriasis

Markham, Trevor; Rogers, S.; Collins, Paul M.

doi:10.1001/archderm.139.3.325

Cited by 99 publications

(100 citation statements)

References 26 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13 In the present study, there was no statistically significant difference in the number of patients who achieved reduction in MPASI ≥75% with both modalities (85.18% on PUVA side and 81.48% on NB-UVB side; p value 0.718). This is in agreement with the previous studies done by Tanew et al 2 who also found statistically similar clearance rates of 43% for PUVA and 33% for NB-UVB, and Markham et al 15 who found very high clearance rates of 100% for both PUVA and NB-UVB. Such high clearance rates can be explained on the basis that the patients in Markham's study were treated until they were completely clear.…”

Section: Discussionsupporting

confidence: 93%

“…13 Regimens similar to ours were used by Tanew et al 2 and Tahir et al 14 while van Weelden et al, 12 Gordon et al 6 and Yones et al 8 used the twice weekly regimens. A very different twice weekly frequency for PUVA and thrice weekly frequency for NB-UVB was used by Dawe et al 4 and Markham et al 15 in their studies. However, the kind of regimens used did not have any effect on the outcome of the study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative Evaluation of Narrow Band Uvb Versus Oral 8-Methoxypsoralen Uva in Chronic Plaque Psoriasis

Talwar¹,

Sapam²,

Rijal³

2016

jemds

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Comparative Evaluation of Narrow Band Uvb Versus Oral 8-Methoxypsoralen Uva in Chronic Plaque Psoriasis

Talwar¹,

Sapam²,

Rijal³

2016

jemds

View full text Add to dashboard Cite

show abstract

“…Despite the numerous trials performed on the efficacy ofPUVA and UVB-NB (16)(17)(18), scarce data are available on the different duration of remission induced by these two phototherapeutic regimens. Our data show that, although the difference of the duration of remission is not statistically significant, a trend is seen and patients treated with PUVA remain clear for a period about 88 days longer than that.of patients treated with UVB-NB.…”

Section: Discussionmentioning

confidence: 99%

The Duration of Clinical Remission of Photochemotherapy and Narrow-Band UV-B Phototherapy in the Treatment of Psoriasis: A Retrospective Study

Brazzelli

Barbagallo

Trevisan

et al. 2008

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

PUVA and UVB-NB phototherapy have an established role in the treatment of moderate-to-severe psoriasis. Even though psoriasis patients often require continuous treatments, inadequate attention is devoted to the duration of remission after the treatment. The purpose of this retrospective study is to assess which phototherapeutic regimen induces a longer remission. Twenty patients with psoriasis were included: 10 patients received PUVA and 10 patients received UVB-NB. We consider as a "cycle" the therapeutic period needed to reach clinical remission. The comparison between the average number of days in remission revealed that PUVA induces a longer remission period than UVB-NB: PUVA 386 days (ds ±321), UVB-NB 298 days (ds ± 257). Although the difference of the duration of remission is not statistically significant, a trend is seen and patients treated with PUVA remain clear for a period about 88 days longer than that of patients treated with UVB-NB. The differences in the duration of remission of psoriasis therapies must be considered in planning a patient's course of treatment.Psoriasis is a chronic inflammatory skin disease that affects about 0.5-4.6% of the general population (1). A variety of therapeutic options to treat psoriasis is available. The choice of treatment depends on the type, spread and severity of psoriasis, on the patient's age, the quality oflife and the consideration of treatment-associated long-term side risks (2).Photochemotherapy (Psoralen plus UVA, 365 nm) (PUVA) and DVB narrow-band (311 nm) phototherapy (UVB-NB) are well established and very efficient treatments for moderate-to-severe psoriasis (3-9).In literature, many trials evaluate the efficacy and adverse effects of therapies, but inadequate attention is devoted to the duration of remission (10), although it is one of the elements that most affects psoriatic patients' quality of life (11)(12). For this reason, the aim of our study is to assess which phototherapeutic regimen induces a longer remission. MATERIALS AND METHODSTwenty patients with moderate-to-severe psoriasis, resistant to topical treatments, were included in the study. The choice between PUVA or UVB-NB therapy was dictated only by the clinical and/or pharmacologic contraindications connected to PUVA therapy, and it had nothing to do with the different clinical forms, the extension or the gravity of psoriasis itself. Ten patients

show abstract

“…In terms of efficacy instead, 311 nm UVB phototherapy is comparable to PUVA therapy, with a better tolerability profile (11).…”

Section: Discussionmentioning

confidence: 99%

“…This process mainly targets T-lymphocytes in the epidermis of skin lesions in atopic and psoriasis patients (10)(11)(12).…”

mentioning

confidence: 99%

Association of Cyclosporine and 311 nM UVB in the Treatment of Moderate to Severe Forms of Psoriasis: A New Strategic Approach

Franchi

Cainelli

Frigerio

et al. 2004

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Psoriasis is aT-lymphocyte mediated autoimmune disease. The response to therapies targeting Tlymphocytes suggest that the latter is a key cell in the pathogenesis of the disease. Cyclosporine (CsA) inhibits the proliferation and the IL-2 dependent expansion of T-lymphocytes. Ultraviolet radiation is an effective treatment for psoriasis. Several studies have demonstrated a significant improvement of the therapeutic response when narrow-band radiation is issued by TL-Ol fluorescent lamp compared to broadband UVB issued by other fluorescent sources. The effects of UVB on the immune system appear to be limited to the cell-mediated compartment of the immune response. In order to reduce the cumulative dose of UVB and limit the toxicity of drugs in the therapy of psoriasis, phototherapy with UVB has been used as treatment in association with other standard therapies. The purpose of the study is to evaluate, in patients with moderate to severe psoriasis a combined therapy with Cyclosporine A and 311 nm UVB phototherapy.

show abstract

Narrowband UV-B (TL-01) Phototherapy vs Oral 8-Methoxypsoralen Psoralen–UV-A for the Treatment of Chronic Plaque Psoriasis

Abstract: Objective: To compare the efficacy of narrowband UV-B (TL-01) phototherapy with oral 8-methoxypsoralen photochemotherapy (8-MOP psoralen-UV-A [PUVA]) in patients with chronic plaque psoriasis (CPP).

Cited by 99 publications

References 26 publications

Comparative Evaluation of Narrow Band Uvb Versus Oral 8-Methoxypsoralen Uva in Chronic Plaque Psoriasis

Comparative Evaluation of Narrow Band Uvb Versus Oral 8-Methoxypsoralen Uva in Chronic Plaque Psoriasis

The Duration of Clinical Remission of Photochemotherapy and Narrow-Band UV-B Phototherapy in the Treatment of Psoriasis: A Retrospective Study

Association of Cyclosporine and 311 nM UVB in the Treatment of Moderate to Severe Forms of Psoriasis: A New Strategic Approach

Contact Info

Product

Resources

About